PSA response to lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: A case report

Case Reports in Oncology

Volumn 5, Issue 1, 2012, Pages 181-186

  Gasent Blesa, Joan Manel ^a,d   Godoy, Miguel Peris ^a   Esparcia, María Fonfría ^a   Mollá, Sara Blasco ^a   Mancheño Magán, Balbino ^b   Sempere Ortells, José Miguel ^b   Sánchez, José Luis ^c  

^a Hospital de Dénia   (Spain)

^b UNIVERSITY OF ALICANTE   (Spain)

^c UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^d Hospital de Dénia M Arina Salud   (Spain)

Author keywords

Hormone resistant prostate cancer; Lenalidomide; Prostate serum antigen

Indexed keywords

BICALUTAMIDE; CAPECITABINE; CYPROTERONE ACETATE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; FENTANYL; GONADORELIN DERIVATIVE; GOSERELIN; IBUPROFEN; KETOCONAZOLE; LACTULOSE; LENALIDOMIDE; MORPHINE SULFATE; OXALIPLATIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SUNITINIB; TESTOSTERONE; VINBLASTINE;

ADULT; ANALGESIA; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DRUG WITHDRAWAL; HEALTH STATUS; HEMATOLOGIC DISEASE; HORMONE RESISTANCE; HORMONE RESISTANT PROSTATE CANCER; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN DISEASE; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION;

EID: 84860721036     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000336481     Document Type: Review

References (18)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Hamberg P, Verhagen PC, de Wit R: When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008;44:1193-1197.
3. Sternberg CN: Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 2008;19(suppl 7):vii91-vii95.
4. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-1237.
5. Lu L, Schafer P, Bartlett JB: Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects within the tumor cell microenvironment. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 2009, Abstract e14620.
6. Zhu D, Corral LG, Fleming YW, et al: Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-1859.
7. Henry J, Lu L, Adams M, et al: Lenalidomide enhances the anti-cancer activity of docetaxel in in vitro and in vivo models of prostate cancer. American Association for Cancer Research 2010, Poster 28468.
8. Garcia JA, Triozzi P, Smith S, et al: Phase I/II study of lenalidomide and GM-CSF in hormone refractory prostate cancer (HRPC). Proceedings of the ASCO Prostate Cancer Symposium 2007, Abstract 229.
9. Moss RA, Mohile SG, Shelton G, Melia J, Petrylak DP: A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Proceedings of the ASCO Prostate Cancer Symposium 2007, Abstract 89.
10. Pagliaro LC, Tannir NM, Tu S, et al: A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy. J Clin Oncol 2008;26(suppl):Abstract 13545.
11. Garcia JA, Triozzi P, Elson P, et al: Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. J Clin Oncol 2008;26(suppl):Abstract 5143.
12. Petrylak DP, Resto-Garces K, Tibyan M, et al: A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 2009;27(suppl):15s:Abstract 5156.
13. Nabhan C, Tolzien K, Kelby SK, et al: Lenalidomide (Revlimid®) has single-agent activity in chemotherapy-naive castration-resistant prostate cancer (CRPC). American Society of Clinical Oncology, Genitourinary Cancer Symposium Meeting 2010, Poster.
14. Lestingi TM, Tolzien K, Kelby SK, et al: Safety and activity of lenalidomide (LEN) in elderly patients (pts) with chemotherapy-naive, castration resistant prostate cancer (CRPC). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 2010, Abstract e15125.
15. Mathew P, Tannir N, Tu SM, et al: A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 2010;65:811-815.
16. Dahut WL, Aragon-Ching JB, Woo S, et al: Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49:650-660.
17. Zhu D, Corral LG, Fleming YW, et al: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-1859.
18. Bubendorf L, Schöpfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.